5-HT2A Receptor Binding in the Frontal Cortex of Parkinson’s Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study
Parkinson’s Disease; http://dx.doi.org/10.1155/2016/3682936.
Cerebrospinal fluid biomarkers and clinical features in leucine‐rich repeat kinase 2 (LRRK2) mutation carriers..
Mov Disord.; doi: 10.1002/mds.26591..
Protein Kinase Cδ Upregulation in Microglia Drives Neuroinflammatory Responses and Dopaminergic Neurodegeneration in Experimental Models of Parkinson's Disease.
NCBI; doi: 10.1016/j.nbd.2016.04.008.
Sensitive analysis of α-synuclein by nonlinear laser wave mixing coupled with capillary electrophoresis
Anal Biochem.; DOI: 10.1016/j.ab.2016.01.010.
Structure–activity relationships of radioiodinated diphenyl derivatives with different conjugated double bonds as ligands for α-synuclein aggregates
RSC Advances; DOI: 10.1039/C6RA02710E.
5-((3-Amidobenzyl)oxy)nicotinamides as Sirtuin 2 Inhibitors.
ACS Publications; DOI: 10.1021/acs.jmedchem.5b01376.
Identification of a specific α-synuclein peptide (α-Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons
Journal of Neuroinflammation; DOI: 10.1186/s12974-016-0606-7.
Altered Alpha-Synuclein, Parkin, and Synphilin Isoform Levels in Multiple System Atrophy Brains
Journal of Neurochemistry; DOI: 10.1111/jnc.13392.
Insulin-degrading enzyme is activated by the C-terminus of α-synuclein
Biochemical and Biophysical Research Communications; doi:10.1016/j.bbrc.2015.09.002.
Drugs which bind to alpha-synuclein. Neuroprotective or neurotoxic?
ACS Chemical; DOI: 10.1021/acschemneuro.5b00172